Cosmos Health Reports Record Q2 2026 Revenue Growth
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Source: Newsfilter
- Significant Revenue Growth: Cosmos Health anticipates Q2 2026 revenue of approximately $19.4 million, reflecting a 31.5% year-over-year increase from $14.75 million in Q2 2025, showcasing the company's strong market performance and growth potential.
- Impressive First Half Performance: The company expects first-half 2026 revenue to reach approximately $37.3 million, up 31% from $28.46 million in H1 2025, marking the highest revenue in its history and further solidifying its market position.
- Share Repurchase Program: As of July 6, 2026, Cosmos Health has repurchased 3,640,000 shares for approximately $700,000 under its $5 million buyback program, indicating confidence in its stock value and plans to continue repurchases as market conditions allow.
- CEO Highlights Growth Momentum: CEO Greg Siokas emphasized that the company achieved record revenues in both Q2 and H1 2026 while actively repurchasing stock to enhance long-term shareholder value, demonstrating strong confidence in future growth prospects.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy COSM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on COSM
About COSM
Cosmos Health Inc. is a diversified, vertically integrated global healthcare company. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life, Mediterranation, bio-bebe, C-Sept and C-Scrub. Through its subsidiary Cana Laboratories S.A., it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. It also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and over-the-counter (OTC) medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the United Kingdom. It also has research and development (R&D) partnerships targeting health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of patented nutraceuticals, specialized root extracts, proprietary complex generics, and OTC products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Cosmos Health Reports Record Q2 2026 Revenue Growth
- Significant Revenue Growth: Cosmos Health anticipates Q2 2026 revenue of approximately $19.4 million, reflecting a 31.5% year-over-year increase from $14.75 million in Q2 2025, showcasing the company's strong market performance and growth potential.
- Impressive First Half Performance: The company expects first-half 2026 revenue to reach approximately $37.3 million, up 31% from $28.46 million in H1 2025, marking the highest revenue in its history and further solidifying its market position.
- Share Repurchase Program: As of July 6, 2026, Cosmos Health has repurchased 3,640,000 shares for approximately $700,000 under its $5 million buyback program, indicating confidence in its stock value and plans to continue repurchases as market conditions allow.
- CEO Highlights Growth Momentum: CEO Greg Siokas emphasized that the company achieved record revenues in both Q2 and H1 2026 while actively repurchasing stock to enhance long-term shareholder value, demonstrating strong confidence in future growth prospects.
See More
Cosmos Health Reports Q2 Revenue Growth and Share Buyback Update
- Revenue Growth: Cosmos Health anticipates Q2 2026 revenue of approximately $19.4 million, representing a 31.5% increase from $14.75 million in Q2 2025, indicating strong market demand for its nutraceutical products.
- First Half Performance: The company expects to report H1 2026 revenue of around $37.3 million, up approximately 31% from $28.46 million in the previous year, reflecting ongoing expansion in the pharmaceuticals and dietary supplements market.
- Share Buyback Program: Cosmos Health has repurchased an additional 230,000 shares at an average price of about $0.2539 per share, totaling 3.87 million shares repurchased for approximately $758,000, demonstrating confidence in its stock value.
- Market Performance: Despite trading between $0.16 and $1.32 over the past year, the stock closed at $0.25, down 4.89%, and further declined 2.26% in after-hours trading, reflecting cautious market sentiment regarding its short-term performance.
See More
Cosmos Health Announces Share Repurchase Update
- Share Repurchase Progress: Cosmos Health has repurchased an additional 230,000 shares at an average price of approximately $0.2539 per share, bringing the total repurchased shares to 3,870,000 for about $758,000, demonstrating the company's confidence in its intrinsic value.
- Repurchase Program Details: The total repurchase program is set at $5 million and is expected to continue until December 31, 2026, with the option for the company to renew based on market conditions, indicating a strategic flexibility in response to market dynamics.
- CEO's Confidence Statement: CEO Greg Siokas stated that the ongoing share repurchase reflects the company's belief that the market undervalues its platform strength and business trajectory, aiming to bolster investor confidence.
- Global Business Expansion: Cosmos Health is solidifying its position in the global healthcare market through diversified investments in pharmaceuticals and nutraceuticals, alongside expansion efforts in Europe, Asia, and North America via its subsidiaries.
See More
Cosmos Health Continues Stock Buyback Program
- Buyback Program Progress: Cosmos Health repurchased an additional 220,000 shares at an average price of approximately $0.2229 per share, bringing the total repurchased shares to 3,640,000 for about $700,000, indicating strong confidence in the stock's value.
- Program Details: The buyback program has a total allocation of $5 million and is set to expire on December 31, 2026, with potential for renewal based on market conditions, aimed at enhancing shareholder trust through capital returns.
- CEO's Confidence Statement: CEO Greg Siokas stated that the ongoing stock repurchases reflect the company's confidence in its operational strength and long-term potential, emphasizing that buybacks remain one of the most compelling investments available to the company.
- Global Business Expansion: In addition to stock buybacks, Cosmos Health, as a diversified global healthcare group, is continuously expanding its operations across Europe, Asia, and North America, focusing on innovation and R&D to enhance its market competitiveness.
See More
Cosmos Health Repurchases 77,000 Shares
- Repurchase Progress: Cosmos Health Inc. announced the buyback of an additional 77,000 shares at a price of $0.1956 per share, bringing the total repurchased shares to approximately 3.42 million at a total cost of $650,000, indicating the company's confidence in its stock value.
- Total Repurchase Limit: The share repurchase program has a total limit of $5 million and is expected to continue until December 31, 2026, demonstrating the company's intention to enhance shareholder value through ongoing market purchases.
- Stock Performance: Cosmos Health closed at $0.24 on Thursday, up 17.61% from the previous trading day, reflecting a positive market reaction to the company's buyback actions, although shares dipped 2.99% in after-hours trading.
- Market Signal: The company's ongoing stock repurchase not only boosts investor confidence but may also elevate the stock price in the future, further solidifying its market position in the healthcare sector.
See More
Cosmos Health Repurchases Additional 770,000 Shares
- Share Buyback Expansion: Cosmos Health has repurchased an additional 770,000 shares at an average price of approximately $0.1956 per share, bringing the total repurchased shares to 3.42 million for about $650,000, reflecting the company's confidence in its current stock price.
- Ongoing Buyback Program: Under a $5 million repurchase program, the company intends to continue open market purchases until December 31, 2026, indicating a proactive approach to capital utilization aimed at enhancing shareholder value.
- CEO Statement: CEO Greg Siokas stated that the steady expansion of buyback activities reflects the company's recognition of the intrinsic value of its diversified global platform, emphasizing the attractiveness of stock repurchases as a capital use.
- Global Expansion Strategy: By acquiring ZipDoctor, Cosmos Health enters the telehealth space and expands throughout Europe, Asia, and North America, showcasing its strategic positioning and growth potential in the global healthcare market.
See More
Cosmos Health Reports Record Q2 2026 Revenue Growth
- Significant Revenue Growth: Cosmos Health anticipates Q2 2026 revenue of approximately $19.4 million, reflecting a 31.5% year-over-year increase from $14.75 million in Q2 2025, showcasing the company's strong market performance and growth potential.
- Impressive First Half Performance: The company expects first-half 2026 revenue to reach approximately $37.3 million, up 31% from $28.46 million in H1 2025, marking the highest revenue in its history and further solidifying its market position.
- Share Repurchase Program: As of July 6, 2026, Cosmos Health has repurchased 3,640,000 shares for approximately $700,000 under its $5 million buyback program, indicating confidence in its stock value and plans to continue repurchases as market conditions allow.
- CEO Highlights Growth Momentum: CEO Greg Siokas emphasized that the company achieved record revenues in both Q2 and H1 2026 while actively repurchasing stock to enhance long-term shareholder value, demonstrating strong confidence in future growth prospects.
See More
Cosmos Health Reports Q2 Revenue Growth and Share Buyback Update
- Revenue Growth: Cosmos Health anticipates Q2 2026 revenue of approximately $19.4 million, representing a 31.5% increase from $14.75 million in Q2 2025, indicating strong market demand for its nutraceutical products.
- First Half Performance: The company expects to report H1 2026 revenue of around $37.3 million, up approximately 31% from $28.46 million in the previous year, reflecting ongoing expansion in the pharmaceuticals and dietary supplements market.
- Share Buyback Program: Cosmos Health has repurchased an additional 230,000 shares at an average price of about $0.2539 per share, totaling 3.87 million shares repurchased for approximately $758,000, demonstrating confidence in its stock value.
- Market Performance: Despite trading between $0.16 and $1.32 over the past year, the stock closed at $0.25, down 4.89%, and further declined 2.26% in after-hours trading, reflecting cautious market sentiment regarding its short-term performance.
See More
Cosmos Health Announces Share Repurchase Update
- Share Repurchase Progress: Cosmos Health has repurchased an additional 230,000 shares at an average price of approximately $0.2539 per share, bringing the total repurchased shares to 3,870,000 for about $758,000, demonstrating the company's confidence in its intrinsic value.
- Repurchase Program Details: The total repurchase program is set at $5 million and is expected to continue until December 31, 2026, with the option for the company to renew based on market conditions, indicating a strategic flexibility in response to market dynamics.
- CEO's Confidence Statement: CEO Greg Siokas stated that the ongoing share repurchase reflects the company's belief that the market undervalues its platform strength and business trajectory, aiming to bolster investor confidence.
- Global Business Expansion: Cosmos Health is solidifying its position in the global healthcare market through diversified investments in pharmaceuticals and nutraceuticals, alongside expansion efforts in Europe, Asia, and North America via its subsidiaries.
See More
Cosmos Health Continues Stock Buyback Program
- Buyback Program Progress: Cosmos Health repurchased an additional 220,000 shares at an average price of approximately $0.2229 per share, bringing the total repurchased shares to 3,640,000 for about $700,000, indicating strong confidence in the stock's value.
- Program Details: The buyback program has a total allocation of $5 million and is set to expire on December 31, 2026, with potential for renewal based on market conditions, aimed at enhancing shareholder trust through capital returns.
- CEO's Confidence Statement: CEO Greg Siokas stated that the ongoing stock repurchases reflect the company's confidence in its operational strength and long-term potential, emphasizing that buybacks remain one of the most compelling investments available to the company.
- Global Business Expansion: In addition to stock buybacks, Cosmos Health, as a diversified global healthcare group, is continuously expanding its operations across Europe, Asia, and North America, focusing on innovation and R&D to enhance its market competitiveness.
See More
Cosmos Health Repurchases 77,000 Shares
- Repurchase Progress: Cosmos Health Inc. announced the buyback of an additional 77,000 shares at a price of $0.1956 per share, bringing the total repurchased shares to approximately 3.42 million at a total cost of $650,000, indicating the company's confidence in its stock value.
- Total Repurchase Limit: The share repurchase program has a total limit of $5 million and is expected to continue until December 31, 2026, demonstrating the company's intention to enhance shareholder value through ongoing market purchases.
- Stock Performance: Cosmos Health closed at $0.24 on Thursday, up 17.61% from the previous trading day, reflecting a positive market reaction to the company's buyback actions, although shares dipped 2.99% in after-hours trading.
- Market Signal: The company's ongoing stock repurchase not only boosts investor confidence but may also elevate the stock price in the future, further solidifying its market position in the healthcare sector.
See More
Cosmos Health Repurchases Additional 770,000 Shares
- Share Buyback Expansion: Cosmos Health has repurchased an additional 770,000 shares at an average price of approximately $0.1956 per share, bringing the total repurchased shares to 3.42 million for about $650,000, reflecting the company's confidence in its current stock price.
- Ongoing Buyback Program: Under a $5 million repurchase program, the company intends to continue open market purchases until December 31, 2026, indicating a proactive approach to capital utilization aimed at enhancing shareholder value.
- CEO Statement: CEO Greg Siokas stated that the steady expansion of buyback activities reflects the company's recognition of the intrinsic value of its diversified global platform, emphasizing the attractiveness of stock repurchases as a capital use.
- Global Expansion Strategy: By acquiring ZipDoctor, Cosmos Health enters the telehealth space and expands throughout Europe, Asia, and North America, showcasing its strategic positioning and growth potential in the global healthcare market.
See More
